Phase 3 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with kidney cancer that has spread to other parts of the body (metastatic renal tumour) at the time of their first diagnosis
- People who have at least one clearly defined, non-calcified spot or growth measuring 3mm or larger — such as a nodule in the lungs or another area showing strong signs of spread — as seen on a CT scan of the chest and a CT scan or MRI of the abdomen
- People whose spread of cancer has been confirmed through a central medical review process
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Emilie GARRIDO-PRADALIE, Assistance Publique Hopitaux De Marseille
Phone: +33.491.38.84.78
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Metastatic response assessment by neoadjuvant chemotherapy only
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.